The presence of four or more copies of the gene RUNX1 in an abnormal chromosome 21 among children with acute lymphoblastic leukemia was associated with poor outcomes, according to a study in the Journal of Clinical Oncology. This gene amplification "helps identify patients who need more therapy than they may otherwise get," study author Dr. Stephen Hunger said.
Genetic marker may predict need for aggressive ALL treatment in children
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|